Zobrazeno 1 - 10 of 150 pro vyhledávání: '"James S Robertson"'
1
Akademický článek
The Ability of a Non-Egg Adapted (Cell-Like) A(H1N1)pdm09 Virus to Egg-Adapt at HA Loci Other than 222 and 223 and Its Effect on the Yield of Viral Protein.
Autor: Carolyn Nicolson, Ruth Harvey, Othmar G Engelhardt, James S Robertson
Publikováno v: PLoS ONE, Vol 11, Iss 11, p e0166761 (2016)
Previous studies on influenza A(H1N1)pdm09 candidate vaccine viruses (CVVs) that had adapted to growth in embryonated chicken eggs by the acquisition of amino acid substitutions at HA positions 222 or 223 showed that improved protein yield could be c
Externí odkaz: https://doaj.org/article/497c20b470c0441a8e52185812e77c5f
Zobrazit plný text záznamu
2
Akademický článek
Permissible variation in the 3' non-coding region of the haemagglutinin genome segment of the H5N1 candidate influenza vaccine virus NIBRG-14 [corrected].
Autor: Rachel E Johnson, Michelle Hamill, Ruth Harvey, Carolyn Nicolson, James S Robertson, Othmar G Engelhardt
Publikováno v: PLoS ONE, Vol 7, Iss 5, p e36241 (2012)
The candidate H5N1 vaccine virus NIBRG-14 was created in response to a call from the World Health Organisation in 2004 to prepare candidate vaccine viruses (CVVs) to combat the threat of an H5N1 pandemic. NIBRG-14 was created by reverse genetics and
Externí odkaz: https://doaj.org/article/638d86473ccf42148e6cfe9882f69a7d
Zobrazit plný text záznamu
3
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment
Autor: Pedro M Folegatti, Daniel Jenkin, Susan Morris, Sarah Gilbert, Denny Kim, James S. Robertson, Emily R. Smith, Emalee Martin, Marc Gurwith, Robert T. Chen
Publikováno v: Vaccine. 40:5248-5262
Replication-deficient adenoviral vectors have been under investigation as a platform technology for vaccine development for several years and have recently been successfully deployed as an effective COVID-19 counter measure. A replication-deficient a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2a2158cf937178aab7ff084776a5194
https://doi.org/10.1016/j.vaccine.2022.06.008
Zobrazit plný text záznamu
4
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines
Autor: Jonathan M. Smith, Richard C. Condit, Thomas P. Monath, Sonali Kochhar, Emily R. Smith, Robert T. Chen, James S. Robertson, Jean-Louis Excler, Denny Kim, Marc Gurwith, George N. Pavlakis, Patricia E. Fast, David Wood
Publikováno v: Vaccine
Nucleic acid (DNA and RNA) vaccines are among the most advanced vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::386c0de2f10acddcb9d2b368d1da3926
https://doi.org/10.1016/j.vaccine.2020.06.017
Zobrazit plný text záznamu
5
Akademický článek
Developing Vaccines to Combat Pandemic Influenza
Autor: Othmar G. Engelhardt, James S. Robertson
Publikováno v: Viruses, Vol 2, Iss 2, Pp 532-546 (2010)
Influenza vaccine manufacturers require antigenically relevant vaccine viruses that have good manufacturing properties and are safe to use. In developing pandemic vaccine viruses, reverse genetics has been employed as a rational approach that can als
Externí odkaz: https://doaj.org/article/447001277faa4e9d91e025656f8b152d
Zobrazit plný text záznamu
6
The INN global nomenclature of biological medicines: A continuous challenge
Autor: James S. Robertson, Robin Thorpe, Sarel F. Malan, Wai Keung Chui, Menico Rizzi, Gilles Mignot, Armando A. Genazzani, Ana López de la Rica Manjavacas, Raffaella Balocco
Publikováno v: Biologicals. 60:15-23
Medicines are assigned International Nonproprietary Names (INN) by the World Health Organization (WHO), pursuing the aim to increase patient safety. Following scientific developments in drug discovery and biotechnology, the number of biological medic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b399f4009b93fd3fa80cc68dd9bc28e6
https://doi.org/10.1016/j.biologicals.2019.05.006
Zobrazit plný text záznamu
7
The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform
Autor: Heinz Weidenthaler, Richard C. Condit, James S. Robertson, Jean-Louis Excler, Ariane Volkmann, Emily R. Smith, Eric Evans, Robert T. Chen, Anna-Lise Williamson, Thomas Meyer, Denny Kim
Publikováno v: Vaccine
The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety and characteristics of live, recombinant viral vector vaccines. The Modified Vaccinia Ankara (MVA) vector system is being explored as a pl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::740fc9b1d04f33c36bc4eac7f7dbe390
http://europepmc.org/articles/PMC7568176
Zobrazit plný text záznamu
10
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines
Autor: Richard C Condit, Denny Kim, James S. Robertson, Jean-Louis Excler, Marc Gurwith, Thomas P. Monath, George Pavlakis, Patricia E. Fast, Jonathan Smith, Emily R. Smith, Robert T. Chen, Sonali Kochhar
Publikováno v: Vaccine
Many of the vaccines under development for COVID-19 involve the use of viral vectors. The Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO, formerly the Viral Vector Vaccine Safety Working Group, V3SWG) working group
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b1594f7e8724706d2f7e241a8ebb01d
https://pubmed.ncbi.nlm.nih.gov/32907759
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje